The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment.
The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
THE PSYCHEDELICS AS MEDICINE REPORT
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report examines:
Essential insights into the nascent psychedelics market
Deep dives into the most transformative compounds and companies
Key regulations, transformative trends and commercial opportunities
V2 COMING AUGUST 2020...
PSYCH Symposium is the industry's most influential virtual conference. Hosted on June 22-23, 2020, as part of Prohibition Partners LIVE, PSYCH Symposium brought together distinguished industry thoughtleaders and rising entrepreneurs to share insights and learnings of this emerging frontier. The inaugural event hosted stakeholders from the political, scientific, medical and business verticals of the global industry to promote the understanding, research and growth of psychedelics as a medicine.
Delegates of the symposium received an in-depth analysis on this new field of medicine, from its regulatory situation, to its clinical evidence and commercial potential. With the limited information currently available on the nascent industry, the PSYCH Symposium marked a significant milestone for this emerging industry. You can watch back some of the highlights from our acclaimed speakers below.
Professor David Nutt
Former Chief Drugs Advisor to the UK Government
Director, Beckley Foundation
PSYCH: What are the next steps for investors?
PSYCH: What Lies Ahead? The Future of Therapy
PSYCH: Psychedelics for Substance Use
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
PSYCH Symposium at Prohibition Partners LIVE brought together world-class speakers, industry giants and pioneering investors, to discuss psychedelics and their potential to disrupt how we treat mental health. Read the highlights.